Previous 10 | Next 10 |
IVERIC bio, Inc. (ISEE) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Offi...
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q1 2022 Earnings Call May 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q1 2022 Earnings Call Transcript
IVERIC bio press release (NASDAQ:ISEE): Q1 GAAP EPS of -$0.29 misses by $0.01. As of March 31, 2022, the Company had approximately $345.7 million in cash, cash equivalents and available-for-sale securities. For further details see: IVERIC bio GAAP EPS of -$0.29 misses by $0.01
- Zimura ® GATHER2 Topline Data Expected in the Third Quarter of this Year- - GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90% – - U.S. Pa...
- Analysis to be Presented at Retinal World Congress in Fort Lauderdale, FL on May 13, 2022 - IVERIC Bio, Inc. (Nasdaq: ISEE) announced today that a post-hoc analysis evaluating the reduction in geographic atrophy (GA) lesion growth observed in patients receiving Zimura ...
IVERIC bio (NASDAQ:ISEE) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market opem. The consensus EPS Estimate is -$0.27 (+6.9% Y/Y) and the consensus Revenue Estimate is $0M. Over the last 3 months, EPS estimates have seen 0 upward revisions and 0 downw...
ABC,AMRN,AMRX,ASC,ATI,AVA,AVNS,BDC,BIP,BLX,BRKR,BRY,BWA,CDW,CFMS,CGAU,CLDT,CLH,CLVS,CMLS,CRL,CRTO,CSII,CVS,DCPH,DIN,DOC,OTCPK:EADSF,EAT,EDIT,EMR,OTCPK:ENLAY,EXPI,EYPT,FDP,FMS,OTCPK:FSNUF,FTS,FUN,GEL,GNRC,GOLD,GTHX,HZNP,IDXX,IMKTA,INSW,IONS,ISEE,JCI,JHG,OTCPK:LBLCF,LITE,LL,LNG,MAR,MCRB,MFA,MIR...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to ...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022, at 9:00 a.m. Eastern Time. Investors and the gene...
Gainers: Sportradar Group AG (SRAD) +5%. Eargo, Inc. (EAR) +4%. Zynex, Inc. (ZYXI) +3%. IVERIC bio, Inc. (ISEE) +3%. Sono Group N.V. (SEV) +3%. Losers: Vir Biotechnology, Inc. (VIR) -8%. Jounce Therapeutics, Inc. (JNCE) -6%. Travelzoo (TZOO) -5%. Health Catalyst, Inc (HCAT) -4%...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...